Showing 4,521 - 4,540 results of 9,598 for search 'significant ((((greater decrease) OR (((we decrease) OR (greatest decrease))))) OR (mean decrease))', query time: 0.46s Refine Results
  1. 4521

    Supplementary Material for: Some peculiarities of MLH1 foci distribution in common degu (Octodon degus, Rodentia: Octodontidae) chromosomes: presence in pericentromeric regions and... by figshare admin karger (2628495)

    Published 2025
    “…Within the heterochromatic blocks located on the chromosome arms and marked by H3K9me3, one of the major constitutive heterochromatin marks, we observed a significant decrease in recombination frequency. …”
  2. 4522

    Supplementary file 1_Active fungal infections alter the respiratory microbiome profiles of Mayo Clinic Arizona patients.zip by Daniel R. Kollath (18134608)

    Published 2025
    “…Additionally, we observed a decrease in diversity in the lung fungal communities in patients with an active Coccidioides or Candida infection but no difference in the bacterial community.…”
  3. 4523

    Influence of Kar4 deletion on low affinity PRE sites. by Sandrine Pinheiro (21553774)

    Published 2025
    “…The O and T indicate a significant difference between the mean of the replicates (t-test: p-val < 0.05) in the timing of induction (T) or in the expression output (O) between the WT and <i>kar4∆</i> strains for the same promoter.…”
  4. 4524

    Data Sheet 1_Apheresis for the treatment of relapses in MS and NMOSD: reduced antibody reactivities, gene expression changes and potential clinical response indicators.pdf by Michael Hecker (51971)

    Published 2025
    “…A gene expression signature that is characteristic of CD4<sup>+</sup> cytotoxic T lymphocytes (CD4-CTLs) was found to be elevated at baseline in non-responders to apheresis, although this could not be validated with statistical significance (n=19 MS patients).</p>Conclusion<p>Our data reveal that therapeutic apheresis in MS rapidly leads to a significant decrease in IgG reactivities against EBNA1 (391-410) and cross-reactive targets such as GlialCAM (370-389) and also has an impact on the gene expression of B cells and T cells. …”
  5. 4525

    Data Sheet 5_Identification of nasopharyngeal microbial dysbiosis in COVID-19 patients by 16S rRNA gene sequencing.xls by Filippos S. Kardaras (18330696)

    Published 2025
    “…When comparing the NE and SE groups, we observed a significant increase in the abundance of the Proteobacteria phylum in the SE group, while the abundance of Fusobacteria was significantly lower in the SE group. …”
  6. 4526

    Data Sheet 2_Identification of nasopharyngeal microbial dysbiosis in COVID-19 patients by 16S rRNA gene sequencing.xls by Filippos S. Kardaras (18330696)

    Published 2025
    “…When comparing the NE and SE groups, we observed a significant increase in the abundance of the Proteobacteria phylum in the SE group, while the abundance of Fusobacteria was significantly lower in the SE group. …”
  7. 4527

    Supplementary file 1_Identification of nasopharyngeal microbial dysbiosis in COVID-19 patients by 16S rRNA gene sequencing.docx by Filippos S. Kardaras (18330696)

    Published 2025
    “…When comparing the NE and SE groups, we observed a significant increase in the abundance of the Proteobacteria phylum in the SE group, while the abundance of Fusobacteria was significantly lower in the SE group. …”
  8. 4528

    Data Sheet 4_Identification of nasopharyngeal microbial dysbiosis in COVID-19 patients by 16S rRNA gene sequencing.xls by Filippos S. Kardaras (18330696)

    Published 2025
    “…When comparing the NE and SE groups, we observed a significant increase in the abundance of the Proteobacteria phylum in the SE group, while the abundance of Fusobacteria was significantly lower in the SE group. …”
  9. 4529

    Data Sheet 1_Identification of nasopharyngeal microbial dysbiosis in COVID-19 patients by 16S rRNA gene sequencing.xls by Filippos S. Kardaras (18330696)

    Published 2025
    “…When comparing the NE and SE groups, we observed a significant increase in the abundance of the Proteobacteria phylum in the SE group, while the abundance of Fusobacteria was significantly lower in the SE group. …”
  10. 4530

    Data Sheet 3_Identification of nasopharyngeal microbial dysbiosis in COVID-19 patients by 16S rRNA gene sequencing.xls by Filippos S. Kardaras (18330696)

    Published 2025
    “…When comparing the NE and SE groups, we observed a significant increase in the abundance of the Proteobacteria phylum in the SE group, while the abundance of Fusobacteria was significantly lower in the SE group. …”
  11. 4531

    Image1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  12. 4532

    Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  13. 4533

    Table 3_Global, regional, and national burden of premenstrual syndrome from 1990 to 2021 and projections to 2050: an analysis based on the 2021 Global Burden of Disease study.xlsx by Ruonan Qiang (22753394)

    Published 2025
    “…Background<p>Premenstrual syndrome (PMS) imposes significant psychological and mental health burdens on women’s reproductive and general well-being. …”
  14. 4534

    Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  15. 4535

    Image 1_MLL4 regulates postnatal palate growth and midpalatal suture development.tif by Jung-Mi Lee (14912426)

    Published 2025
    “…Additionally, SOX9, a master regulator of chondrogenesis, exhibited a significant decrease in protein expression. Indeed, time-course histological analysis during postnatal palate growth revealed retardation in the development of the suture cartilage in Mll4-cKO mice. …”
  16. 4536

    Data Sheet 1_MLL4 regulates postnatal palate growth and midpalatal suture development.csv by Jung-Mi Lee (14912426)

    Published 2025
    “…Additionally, SOX9, a master regulator of chondrogenesis, exhibited a significant decrease in protein expression. Indeed, time-course histological analysis during postnatal palate growth revealed retardation in the development of the suture cartilage in Mll4-cKO mice. …”
  17. 4537

    Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  18. 4538

    Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  19. 4539

    Image3_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  20. 4540

    Table 1_Global, regional, and national burden of premenstrual syndrome from 1990 to 2021 and projections to 2050: an analysis based on the 2021 Global Burden of Disease study.xlsx by Ruonan Qiang (22753394)

    Published 2025
    “…Background<p>Premenstrual syndrome (PMS) imposes significant psychological and mental health burdens on women’s reproductive and general well-being. …”